Humacyte, Inc. (NASDAQ:HUMA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Humacyte, Inc. (NASDAQ:HUMA) has received a consensus rating of “Moderate Buy” from the eight brokerages that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and seven have given a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $6.25.

Several brokerages have recently commented on HUMA. Benchmark lifted their target price on Humacyte to $2.00 and gave the stock a “speculative buy” rating in a research report on Monday, June 1st. Weiss Ratings restated a “sell (e+)” rating on shares of Humacyte in a research note on Wednesday, July 8th. BTIG Research reaffirmed a “buy” rating and issued a $2.00 price objective on shares of Humacyte in a report on Tuesday, July 28th. D. Boral Capital reiterated a “buy” rating and set a $25.00 target price on shares of Humacyte in a research note on Tuesday, April 28th. Finally, TD Cowen dropped their target price on shares of Humacyte from $1.50 to $1.25 and set a “buy” rating on the stock in a report on Wednesday, June 17th.

Insider Buying and Selling

In other news, CFO Dale A. Sander sold 45,887 shares of the company’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $0.90, for a total transaction of $41,298.30. Following the completion of the transaction, the chief financial officer owned 267,213 shares in the company, valued at approximately $240,491.70. This represents a 14.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Shamik J. Parikh sold 45,887 shares of the company’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $0.90, for a total transaction of $41,298.30. Following the completion of the transaction, the insider owned 272,713 shares of the company’s stock, valued at approximately $245,441.70. This trade represents a 14.40% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 3.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. R Squared Ltd purchased a new stake in shares of Humacyte during the fourth quarter valued at $25,000. Atom Investors LP purchased a new position in Humacyte in the 4th quarter worth about $25,000. Prudential Financial Inc. acquired a new stake in Humacyte during the 2nd quarter worth about $28,000. Financial Advisors Network Inc. acquired a new stake in Humacyte during the 2nd quarter worth about $28,000. Finally, Equitable Holdings Inc. purchased a new stake in Humacyte during the third quarter valued at about $29,000. Institutional investors own 44.71% of the company’s stock.

Humacyte Price Performance

Shares of HUMA stock opened at $0.74 on Tuesday. The firm has a fifty day simple moving average of $0.84 and a 200-day simple moving average of $0.91. The company has a market capitalization of $165.29 million, a PE ratio of -1.31 and a beta of 2.54. Humacyte has a twelve month low of $0.55 and a twelve month high of $2.55. The company has a current ratio of 3.93, a quick ratio of 3.32 and a debt-to-equity ratio of 5.46.

Humacyte (NASDAQ:HUMA) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. The firm had revenue of $0.49 million during the quarter, compared to the consensus estimate of $1.46 million. Humacyte had a negative return on equity of 2,914.18% and a negative net margin of 4,836.06%. Equities research analysts anticipate that Humacyte will post -0.34 earnings per share for the current fiscal year.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.